News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Active Biotech AB (BTPC) Year-End Report January - December 2012



2/14/2013 9:24:09 AM

LUND, SWEDEN--(Marketwire - February 14, 2013) -


Events for the full year 2012

Laquinimod

* Phase III data presented at the AAN (64th Annual Meeting of the American Academy of Neurology)

* Application submitted for regulatory approval in the EU, milestone payment of USD 5 M from Teva

* Teva initiates a Phase III study in multiple sclerosis (the CONCERTO study) in the US

* Positive Crohn's Phase II data presented at the UEGW conference

* Teva expands the clinical development program to encompass new indications


TASQ

* EUR 10 M milestone payment from Ipsen upon 600 patients enrolled in Phase III study

* overall survival data from Phase II study presented

* biomarker data presented at the ESMO conference

* Ipsen initiated two new Phase II trials; a "switch maintenance" in prostate cancer and a second study into additional cancer forms

* Phase III study fully enrolled (1,245 patients); milestone payment of EUR 10 M from Ipsen


ANYARA

* Phase II/III study in renal cell cancer concluded

* Results presented during Q1, 2013:

- study did not achieve primary clinical endpoint

- doubling of progression free survival and OS in 25 % of patients

- planning of the continued clinical development ongoing


57-57

* clinical trial of systemic sclerosis/scleroderma concluded


ISI

* focus on patent submissions H1 2013

* project proceeds as planned

Oct - Dec Jan - Dec (MSEK) 2012 2011 2012 2011 --------------------------------------------------------------------------- * Net sales 91.5 3.3 227.9 234.6 * Operating profit/loss 5.5 -94.7 -163.2 -100.9 * Net profit/loss 0.1 -93.2 -175.0 -94.5 * Profit/loss per share (SEK) 0.00 -1.35 -2.54 -1.38

This report is also available at www.activebiotech.com

Active Biotech AB Year-end report Jan-Dec 2012: http://hugin.info/1002/R/1678129/547591.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1678129]


For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam
CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax +46 (0)46 19 11 00


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES